{"id":501006,"date":"2020-08-07T06:48:01","date_gmt":"2020-08-07T06:48:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=501006"},"modified":"2020-08-07T06:48:01","modified_gmt":"2020-08-07T06:48:01","slug":"pulmonary-arterial-hypertension-clinical-trial-insight-pipeline-assessment-emerging-drugs-and-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pulmonary-arterial-hypertension-clinical-trial-insight-pipeline-assessment-emerging-drugs-and-companies-by-delveinsight_501006.html","title":{"rendered":"Pulmonary Arterial Hypertension Clinical Trial Insight, Pipeline Assessment, Emerging Drugs and Companies by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Pulmonary Arterial Hypertension Clinical Trial Insight, Pipeline Assessment, Emerging Drugs and Companies by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Pulmonary Arterial Hypertension Clinical Trial Insight, Pipeline Assessment, Emerging Drugs and Companies by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>&#8220;Pulmonary Arterial Hypertension Pipeline Insight, 2020&#8221;<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">(Albany, US)&nbsp;<strong>DelveInsight launched a new report on <\/strong><strong>Pulmonary Arterial Hypertension Pipeline Insight, 2020<\/strong><strong>.<\/strong><strong><br \/> <\/strong><br \/> &#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-pipeline-insight\" target=\"_blank\"><strong>Pulmonary Arterial Hypertension Pipeline Insight, 2020<\/strong><\/a>&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;<strong>Pulmonary Arterial Hypertension&nbsp;<\/strong>market. A detailed picture of the&nbsp;<strong>Pulmonary Arterial Hypertension&nbsp;<\/strong>pipeline landscape is provided, which includes the disease overview and&nbsp;<strong>Pulmonary Arterial Hypertension&nbsp;<\/strong>treatment guidelines.<\/p>\n<p style=\"text-align: justify;\">The assessment part of the report embraces in-depth&nbsp;<strong>Pulmonary Arterial Hypertension&nbsp;<\/strong>commercial assessment and clinical assessment of the&nbsp;<strong>Pulmonary Arterial Hypertension&nbsp;<\/strong>pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,&nbsp;<strong>Pulmonary Arterial Hypertension&nbsp;<\/strong>collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\"><strong>Drugs covered<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Aurora-GT<br \/> 2. Ralinepag<br \/> 3. Bardoxolone Methyl<br \/> 4. Rodatristat Ethyl<br \/> 5. Sotatercept<br \/> And many others<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pulmonary-arterial-hypertension-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/pulmonary-arterial-hypertension-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>The key players in Pulmonary Arterial Hypertension market are:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. United Therapeutics<br \/> 2. Liquidia Technologies<br \/> 3. Reata Pharmaceuticals<br \/> 4. Altavant Sciences<br \/> 5. Acceleron Pharma<br \/> And many others<\/p>\n<p> <strong>Key benefits of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The&nbsp;<strong>Pulmonary Arterial Hypertension&nbsp;<\/strong>report provides an overview of&nbsp;<em>therapeutic pipeline activity and therapeutic assessment of the products<\/em>&nbsp;by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<em>for&nbsp;<\/em><strong>Pulmonary Arterial Hypertension&nbsp;<\/strong>across the complete product development cycle, including all clinical and nonclinical stages.<\/li>\n<li>It comprises of&nbsp;<em>detailed profiles of&nbsp;<\/em><strong>Pulmonary Arterial Hypertension&nbsp;<\/strong><em>therapeutic products<\/em>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/li>\n<li>Detailed&nbsp;<strong>Pulmonary Arterial Hypertension&nbsp;<\/strong><em>research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.<\/li>\n<li><em>Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across&nbsp;<strong>Pulmonary Arterial Hypertension<\/strong>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">\n<p> <strong><em>&#8220;The disease is found to be more common among women as compared to men.&#8221;<\/p>\n<p> <\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pulmonary-arterial-hypertension-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/pulmonary-arterial-hypertension-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-pipeline-insight\" target=\"_blank\"><strong>Pulmonary Arterial Hypertension<\/strong><\/a> therapeutic market is driven by the use of endothelin receptor antagonists, prostanoids, and phosphodiesterase inhibitors for the Pulmonary Arterial Hypertension treatment. Among these therapeutics endothelin receptor antagonists are most widely used for the treatment of Pulmonary Arterial Hypertension.<\/p>\n<p> LetairisVolibris(GlaxoSmithKline plcGilead Science), Opsumit (Actelion Pharmaceuticals Ltd), and Tracleer (Actelion Pharmaceuticals Ltd) are mostly recommended endothelin receptor antagonists being used for the Pulmonary Arterial Hypertension treatment. These antagonists act by relaxing blood vessels and inhibiting proliferation and remodelling of blood vessels. LetairisVolibris (GlaxoSmithKline plcGilead Science), which is a selective Endothelin Type-A (ETA) receptor antagonist is the most robust therapeutic as compared to the other endothelin receptor antagonists (ERAs).<\/p>\n<p> Tracleer (Actelion Pharmaceuticals Ltd) is the first endothelin receptor antagonists being approved by the US FDA for treating Pulmonary Arterial Hypertension. Opsumit (Actelion Pharmaceuticals Ltd) is a tissue- targeting endothelin receptor antagonist indicated explicitly for the treatment of pulmonary arterial hypertension (WHO Group I) to delay disease progression. There are large numbers of Prostacyclin\/Prostanoids being available for Pulmonary Arterial Hypertension treatment. There are very few numbers of drugs targeting phosphodiesterase for the treatment of Pulmonary Arterial Hypertension. Revatio (Pfizer) and Adcirca (Eli Lilly and CoGSKUnited Corporation) are the two approved phosphodiesterase inhibitors which act by suppressing high blood pressure by releasing nitric oxide. Revatio (Pfizer) helps in improving pulmonary blood flow. Several studies have reported the use of Adcirca (Eli Lilly and CoGSKUnited Corporation) in improving patient compliance due to once a day dosing.<\/p>\n<p> Overall with the increase in the prevalence of this disease along with the approval of the pipeline therapies, it shall create a positive impact on the Pulmonary Arterial Hypertension treatment market during the forecast period (2020&ndash;2030).<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pulmonary-arterial-hypertension-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/pulmonary-arterial-hypertension-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. Report Introduction<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>2. Pulmonary Arterial Hypertension&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">2.1. Overview<\/p>\n<p style=\"text-align: justify;\">2.2. History&nbsp;<\/p>\n<p style=\"text-align: justify;\">2.3. Pulmonary Arterial Hypertension Symptoms<\/p>\n<p style=\"text-align: justify;\">2.4. Causes<\/p>\n<p style=\"text-align: justify;\">2.5.Pathophysiology<\/p>\n<p style=\"text-align: justify;\">2.6. Pulmonary Arterial Hypertension Diagnosis&nbsp;<\/p>\n<p style=\"text-align: justify;\">2.6.1. Diagnostic Guidelines<\/p>\n<p style=\"text-align: justify;\"><strong>3. Pulmonary Arterial Hypertension&nbsp;Current Treatment Patterns<\/strong><\/p>\n<p style=\"text-align: justify;\">3.1. Pulmonary Arterial Hypertension Treatment Guidelines<\/p>\n<p style=\"text-align: justify;\"><strong>4. Pulmonary Arterial Hypertension&nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/strong><\/p>\n<p style=\"text-align: justify;\">4.1. In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">4.1.1. Pulmonary Arterial Hypertension&nbsp;companies collaborations, Licensing, Acquisition -Deal Value Trends<\/p>\n<p style=\"text-align: justify;\">4.1.1.1. Assessment Summary<\/p>\n<p style=\"text-align: justify;\">4.1.2. Pulmonary Arterial Hypertension&nbsp;Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">4.1.2.1. Company-Company Collaborations (Licensing \/ Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">4.1.2.2. Company-University Collaborations (Licensing \/ Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">4.1.2.3. Pulmonary Arterial Hypertension&nbsp;Acquisition Analysis<\/p>\n<p style=\"text-align: justify;\"><strong>5. Therapeutic Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">5.1. Clinical Assessment of Pipeline Drugs&nbsp;<\/p>\n<p style=\"text-align: justify;\">5.1.1. Assessment by Phase of Development<\/p>\n<p style=\"text-align: justify;\">5.1.2. Assessment by Product Type (Mono \/ Combination)<\/p>\n<p style=\"text-align: justify;\">5.1.2.1. Assessment by Stage and Product Type<\/p>\n<p style=\"text-align: justify;\">5.1.3. Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify;\">5.1.3.1. Assessment by Stage and Route of Administration<\/p>\n<p style=\"text-align: justify;\">5.1.4. Assessment by Molecule Type<\/p>\n<p style=\"text-align: justify;\">5.1.4.1. Assessment by Stage and Molecule Type<\/p>\n<p style=\"text-align: justify;\">5.1.5. Assessment by MOA<\/p>\n<p style=\"text-align: justify;\">5.1.5.1. Assessment by Stage and MOA<\/p>\n<p style=\"text-align: justify;\">5.1.6. Assessment by Target<\/p>\n<p style=\"text-align: justify;\">5.1.6.1. Assessment by Stage and Target<\/p>\n<p style=\"text-align: justify;\"><strong>6. Pulmonary Arterial Hypertension Late Stage Products (Phase-III)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>7. Pulmonary Arterial Hypertension Mid Stage Products (Phase-II)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>8. Early Stage Products (Phase-I)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>9. Pre-clinical Products and Discovery Stage Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>10. Inactive Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>11. Dormant Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>12. Pulmonary Arterial Hypertension Discontinued Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>13. Pulmonary Arterial Hypertension&nbsp;Product Profiles<\/strong><\/p>\n<p style=\"text-align: justify;\">13.1. Drug Name: Company&nbsp;<\/p>\n<p style=\"text-align: justify;\">13.1.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.1.1.1. Product Overview<\/p>\n<p style=\"text-align: justify;\">13.1.1.2. Mechanism of action<\/p>\n<p style=\"text-align: justify;\">13.1.2. Research and Development<\/p>\n<p style=\"text-align: justify;\">13.1.2.1. Clinical Studies<\/p>\n<p style=\"text-align: justify;\">13.1.3. Product Development Activities<\/p>\n<p style=\"text-align: justify;\">13.1.3.1. Collaboration<\/p>\n<p style=\"text-align: justify;\">13.1.3.2. Agreements<\/p>\n<p style=\"text-align: justify;\">13.1.3.3. Acquisition&nbsp;<\/p>\n<p style=\"text-align: justify;\">13.1.3.4. Patent Detail<\/p>\n<p style=\"text-align: justify;\">13.1.4. Tabulated Product Summary<\/p>\n<p style=\"text-align: justify;\">13.1.4.1. General Description Table<\/p>\n<p style=\"text-align: justify;\">Detailed information in the report?&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>14. Pulmonary Arterial Hypertension&nbsp;Key Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>15. Pulmonary Arterial Hypertension&nbsp;Key Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>16. Dormant and Discontinued Products<\/strong><\/p>\n<p style=\"text-align: justify;\">16.1. Dormant Products<\/p>\n<p style=\"text-align: justify;\">16.1.1. Reasons for being dormant<\/p>\n<p style=\"text-align: justify;\">16.2. Discontinued Products&nbsp;<\/p>\n<p style=\"text-align: justify;\">16.2.1. Reasons for the discontinuation<\/p>\n<p style=\"text-align: justify;\"><strong>17. Pulmonary Arterial Hypertension&nbsp;Unmet Needs<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>18. Pulmonary Arterial Hypertension&nbsp;Future Perspectives<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>19. Pulmonary Arterial Hypertension&nbsp;Analyst Review&nbsp;&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>20. Appendix<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>21. Report Methodology<\/strong><\/p>\n<p style=\"text-align: justify;\">21.1. Secondary Research<\/p>\n<p style=\"text-align: justify;\">21.2. Expert Panel Validation&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC:&nbsp;<\/strong><strong>https:\/\/www.delveinsight.com\/sample-request\/pulmonary-arterial-hypertension-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><br \/> DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<br \/><strong><br \/><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=pulmonary-arterial-hypertension-clinical-trial-insight-pipeline-assessment-emerging-drugs-and-companies-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=pulmonary-arterial-hypertension-clinical-trial-insight-pipeline-assessment-emerging-drugs-and-companies-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Pulmonary Arterial Hypertension Pipeline Insight, 2020&#8221; (Albany, US)&nbsp;DelveInsight launched a new report on Pulmonary Arterial Hypertension Pipeline Insight, 2020. &#8220;Pulmonary Arterial Hypertension Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/pulmonary-arterial-hypertension-clinical-trial-insight-pipeline-assessment-emerging-drugs-and-companies-by-delveinsight_501006.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-501006","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/501006","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=501006"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/501006\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=501006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=501006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=501006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}